

(d) the amino acid sequence of a fragment of amino acid residues 1 to 168 of SEQ ID NO:2, wherein said fragment has a biological activity of a polypeptide consisting of residues 1 to 168 of SEQ ID NO:2;

(e) the amino acid sequence of a fragment of the polypeptide encoded by the human cDNA contained in ATCC Deposit No. 97132, wherein said fragment has a biological activity of a polypeptide consisting of residues 1 to 168 of SEQ ID NO:2;

(f) the amino acid sequence of at least 30 contiguous amino acid residues of SEQ ID NO:2; and

(g) a fragment having at least 30 contiguous amino acid residues of the polypeptide encoded by the human cDNA in ATCC Deposit No. 97132.

58. The isolated polypeptide of claim 57, comprising the amino acid sequence of (a).

59. The isolated polypeptide of claim 57, comprising the amino acid sequence of (b).

60. The isolated polypeptide of claim 57, comprising the amino acid sequence of (c).

61. The isolated polypeptide of claim 57, comprising the amino acid sequence of (d).

62. The isolated polypeptide of claim 57, comprising the amino acid sequence of (e).

63. The isolated polypeptide of claim 57, comprising the amino acid sequence of (f).

64. The isolated polypeptide of claim 57, comprising the amino acid sequence of (g).

65. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence shown as residues 1 to 168 of SEQ ID NO:2, wherein said amino acid sequence contains conservative amino acid residue substitutions, and further wherein said amino acid sequence has a biological activity of a polypeptide consisting of residues 1 to 168 of SEQ ID NO:2; and

(b) the amino acid sequence of the mature polypeptide encoded by the human cDNA contained in ATCC Deposit No. 97132, wherein said amino acid sequence contains conservative amino acid residue substitutions, and further wherein said amino acid sequence has a biological activity of a polypeptide consisting of residues 1 to 168 of SEQ ID NO:2.

66. The isolated polypeptide of claim 65, comprising the amino acid sequence of (a).

67. The isolated polypeptide of claim 65, comprising the amino acid sequence of (b).

68. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of a polypeptide encoded by a polynucleotide which hybridizes to the complement of the nucleotide sequence set forth as SEQ ID NO:1, wherein said polypeptide has a biological activity of a polypeptide consisting of residues 1 to 168 of SEQ ID NO:2; and

(b) the amino acid sequence of a polypeptide encoded by a polynucleotide which hybridizes to the human cDNA contained in ATCC Deposit No. 97132, wherein said polypeptide has a biological activity of a polypeptide consisting of residues 1 to 168 of SEQ ID NO:2.

69. The isolated polypeptide of claim 68, comprising the amino acid sequence of (a).

70. The isolated polypeptide of claim 68, comprising the amino acid sequence of (b).

71. The isolated polypeptide of claim 57, wherein said polypeptide is further fused to a heterologous polypeptide.

72. The isolated polypeptide of claim 65, wherein said polypeptide is further fused to a heterologous polypeptide.

73. The isolated polypeptide of claim 68, wherein said polypeptide is further fused to a heterologous polypeptide.

74. A composition comprising the isolated polypeptide of claim 57 in a pharmaceutically acceptable carrier.

75. A composition comprising the isolated polypeptide of claim 65 in a pharmaceutically acceptable carrier.

76. A composition comprising the isolated polypeptide of claim 68 in a pharmaceutically acceptable carrier.

77. The polypeptide of claim 63, wherein said polypeptide has at least 50 contiguous amino acid residues of SEQ ID NO:2.